注射用重组人白细胞介素-12用于治疗恶性肿瘤的研究

Abstract
Figure/Table
References
Related Citation (2)

Download: PDF (5342 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of rhIL-12 on the hemopoietic function, immune function, radiation protection function and tumor evaluation indexes in the tumor radiotherapy group and advanced palliative treatment group.Methods There were 53 cases of tumor patients treated with Cyber knife in treatment group, including 19 cases of 150 ng/kg, 24 cases of 250 ng/kg, and 10 cases of control. There were 47 cases of cancer patients in advanced palliative treatment group, including 20 cases of 150 ng/kg, 21 cases of 250 ng/kg, and 6 cases of control. rhIL-12 was given on the day of treatment and the therapeutic effect was observed for 4 consecutive weeks. The dose-effect relationship was studied.Results RhIL-12 could significantly inhibit the decline of blood cells, prevent immune disorders and reduce radiation injury in the two groups. After the first-dose, there were 19 cases of fever, 9 cases of discomfor, 2 cases of slight changes in serum aminotransferase and bilirubin. There was no other adverse event.Conclusions rhIL-12 may be a safe and effective drug for cancer prevention and treatment in clinical practice.

Key words： rhIL-12 radiosurgery advanced tumor research

Received: 26 October 2016

ZTFLH:

R73.1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Wenqin
	ZHAO Yi
	GONG Xiaojing
	YU Weina
	YANG Lirong
	GAO Lei
	SHEN Hongyu
	WAN Lingqin
	JIA Xifeng
	GUO Na
	and WANG Yishan

Cite this article:

WANG Wenqin,ZHAO Yi,GONG Xiaojing等. Clinical effect of recombinant human interleukin-12 for injection on malignant tumor[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2017, 28(2): 165-170.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2017/V28/I2/165

[1]	Floros T, Tarhini A A. Anticancer cytokines: biology and clinical effects of IFN-γ2, IL-2, IL-15, IL-21, and IL-12[J]. Semin Oncol, 2015, 42(4): 539-548.
[2]	熊国林,赵毅,邢爽,等. rhIL-12对恒河猴造血系统辐射防护作用的初步研究[J]. 中国实验血液学杂志, 2013, 21(1): 150-154.
[3]	Watford W T, Moriguchi M, Morinobu A, et al. The biology of IL-12: coordinating innate and adaptive immune responses[J]. Cytokine Growth Fact Rev, 2003, 14(5): 361-368.
[4]	Dowell A C, Oldham K A, Bhatt R I, et al. Long-term proliferation of functional human NK Cells, with conversion of CD56 (dim) NK cells to a CD56 (bright) phenotype, induced by carcinoma cells co-expressing 4-1BBL and IL-12[J]. Cancer Immunol Immunother, 2012, 61(5): 615-628.
[5]	Smyth M J, Taniguchi M, Street S E. The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent[J]. J Immunol, 2000, 165(5): 2665-2670.
[6]	Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity[J]. Nature Reviews Immunol, 2003, 3(2): 133-146.
[7]	Chen T, Burke K A, Zhan Y, et al. IL-12 facilitates both the recovery of endogenous hematopoiesis and the engraftment of stem cells after ionizing radiation[J]. Exp Hematol, 2007, 35: 203-213.
[8]	Basile L A, Ellefson D, Gluzman-Poltorak Z, et al. HemaMax, a recombinant human interleukin-12, is a potent mitigator of acute radiation injury in mice and non-human primates[J]. PLos One, 2012, 7(2): e30434.
[9]	Gerber S A, Cummings R J, Judge J L, et al. Interleukin-12 preserves the cutaneous physical and immunological barrier after radiation exposure[J]. Radiat Res, 2015,183(1): 72-81.
[10]	Little R F, Aleman K, Kumar P, et al. Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma[J]. Blood, 2007, 110(13): 4165-4171.
[11]	Bekaii-Saab T S, Roda J M, Guenterberg K D, et al. A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignancies[J]. Mol Cancer Ther, 2009, 8(11): 2983-2991.
[12]	Lenzi R, Edwards R, June C, et al. Phase II study of intraperitoneal recombinant interleukin-12(rhIL-12) in patients with peritoneal carcinomatosis(residual disease<1 cm) associated with ovarian cancer or primary peritoneal carcinoma[J]. J Transl Med, 2007, 5: 66.
[13]	Lacy M Q, Jacobus S, Blood E A, et al. Phase II study of interleukin-12 for treament of plateau phase multiple myeloma(E1A96): a trial of the Eastern Cooperative Oncology Group[J]. Leuk Res, 2009, 33(11): 1485-1489.
[14]	Gollob J A, Mier J W, Veenstra K,et al.Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN- induction is associated with clinical response[J]. Clin Cancer Res, 2000, 6(5): 1678-1692.
[15]	Carreo V,Zeuzem S,Hopf U,et al.A phase Ⅰ/Ⅱ study of recombinant human interleukin-12 in patients with chronic hepatitis B[J]. J Hepatology, 2000, 32(2): 317-324.
[16]	Jackson J D, Yan Y, Brunda M J, et al. Interleukin-12 enhances peripheral hematopoiesis in vivo[J]. Blood, 1995, 85(9): 2371-2376.